Press release content from Globe Newswire. The AP news staff was not involved in its creation.
T-knife Announces Appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. .
AKAMPIONJanuary 19, 2021 GMT
San Francisco, CA / Berlin, Germany – January 19, 2021 T-knife GmbH, a next-generation adoptive T-cell therapy company leveraging its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, today announced the appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. Landis as Chief Business Officer & Chief Financial Officer. Elisa Kieback, T-knife’s co-founder and founding CEO, has assumed the role of Chief Technical Officer.
“We welcome Tom and Camille to T-knife and look forward to their contributions as we continue to build our best-in-class T-cell receptor platform, advance our pipeline of innovative cell therapies, and transition to becoming a clinical-stage company in 2021,” stated Alexander Mayweg, Ph.D